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1. Abbreviations used in this paper: BSC-1, basic cell culture number 1; HFF, human foreskin fibroblast cells; HSV-1, herpes simplex virus, type-1; MEF, primary mouse embryo fibroblasts; pfu, placque-forming units; RK, primary rabbit kidney cells. component designated as ab and b'a' are each approximately 9 kb in length whereas those of the S component designated as a'c' and ca are each approximately 6 .5 kbp in length (3, 4) . The two components invert relative to each other and one of the four equimolar isomers was designated as the prototype (5). The shared a sequence in the HSV-I (F) strain is approximately 500 bp in length (6) . Interest in the function of the a sequence led to the discovery that in one specific orientation it functions as a promoter (7) . Subsequent studies revealed that the a sequence promotes the transcription of a RNA that encodes a protein 263 amino acids in length (7) (8) (9) . The gene, designated as y,34.5, is located in the b sequence of the inverted repeats flanking Us sequences, between the a sequence and the transcription initiation ofthe a0 gene and, therefore, it is present in two copies per genome (4) .
Interest in this gene stems from numerous observations that genomic sequences encoding factors or cis-acting sites associated with virulence map at the right terminus ofthe L component of HSV DNA when this DNA is displayed in the prototype arrangement. Centifano and colleagues utilized marker transfer experiments to move a fragment of HSV DNA from a virulent to an avirulent strain of HSV-1 ( 10). Removing genes located at the terminus of the UL sequence of HSV DNA, a prototype HSV vaccine strain could be rendered avirulent (11) . Other investigators, using HSV-1 X HSV-2 recombinants, demonstrated that insertion of HSV-2 sequences at the terminus of the HSV-1 UL sequence resulted in an avirulent virus ( 12, 13) . Virulence was with the insertion ofthe homologous HSV-1 fragment. Taha et al. (14) (15) (16) described spontaneous HSV-2 deletion mutants, lacking less than 1.5 kbp at the termini of the L component, which were less virulent than a recombinant obtained by marker rescue.
To determine the ability to grow in the central nervous system (CNS), one hallmark of neurovirulence, a series of mutant viruses were constructed ( Fig. 1 ) and tested which ofthese viruses map within the coding sequences of-y,34.5. For mutant R3616, 1 kbp was deleted in both copies of the coding sequences of the gene. To insure that the phenotype of the mutant reflected the deletions only, the deleted sequences were restored in both copies of the gene by marker rescue, [HSV-1 (F)R]. To control for the possibility that the deletions cause gross perturbations of the viral genome, a stop codon was inserted into the open reading frame of both copies ofthe y 134.5 gene. This mutant was designated as R4009. In studies published elsewhere, it was shown that the mortality resulting from direct inoculation into the brain of mutant viruses R36 16 and R4009 was reduced by a factor of over six logs as compared to either the parent, HSV-I (F), or the restored, HSV-I (F) R, viruses ( 17) . Although the -y34.5 gene appears to be nonessential for viral replication in cell culture, the product of the gene appeared to be essential for the ability of the virus to replicate in the CNS and produce mortality in the mouse ( 17). We report for the first time, to our knowledge, studies which characterize the contribution of the 'y 34.5 to the biologic properties of HSV-1 and, in particular, define the ability of these mutants to replicate in peripheral tissues of mice, to establish latency in the trigeminal and dorsal root ganglia, and to be reactivated from explanted sensory ganglia. We believe that these results are directly applicable to the development of live, attenuated, genetically engineered HSV vaccines.
Methods
Viruses and cells. The isolation and properties of HSV-I (F) have been previously described (18 ) . The construction of R36 16, R4009, and the restored HSV-l (F)R have been described elsewhere (17) . These viruses were passaged only once prior to freezing for future studies. (19) . Animals (five mice per group) were killed on days 1, 3, 5, and 7. Trigeminal ganglia and brain tissue were harvested, homogenized (10% wt/vol), and assayed on RK cells to determine the quantity of infectious virus. Trigeminal ganglia were removed from parallel groups of animals on day 28 for quantitation of latent virus. The second model evaluated the ability of these viruses to replicate in the eye, CNS, and trigeminal ganglia following inoculation by the ocular route (20) . Suspensions of virus preparations at a concentration of 1038 to 1052 were inoculated on the surface of scarified cornea (20 ul1/eye) of Balb/C mice bilaterally. The eyes were examined sequentially for evidence of ocular disease. These examinations consisted of visual assessment of conjunctival edema and erythema, corneal lesions, and corneal opacification. Mice (five mice per group) were killed on days 1, 2, 3,4, 5, and 7, and both eyes from each animal were harvested for quantitation of infectious virus. Tissue homogenization and inoculation were performed as noted above. Additionally, 10 mice were infected at day 0, killed at day 30, and the trigeminal ganglia processed, as noted below, for evaluation of latent virus. The third model evaluated the ability of these viruses to replicate in the vaginal tract, invade into local peripheral nerves, and establish latency in the sensory ganglia of both Balb/C and Swiss Webster mice after intravaginal inoculation (20) . 20 Swiss Webster and 25 Balb/c mice per virus were inoculated intravaginally with 104 or 106 pfu in 50 41 with cotton-tipped applicators. Vaginal swabs were collected on days 1, 3, 5, and 7 for quantitation of infectious virus. Sacral-dorsal ganglia were removed from the Swiss Webster mice (20 mice per group) on days 1, 3, 5, and 8 postinfection, homogenized, and assayed for the presence of infectious virus. In addition, 10 Balb/C and 5 Swiss Webster mice per virus were killed on day -30, and sacral ganglia were collected for reactivation of latent virus.
Finally, groups of 10 guinea pigs were inoculated intravaginally with 106 pfu's of each of the four viruses (21) (22) (23) . Infection was accomplished by use of virus-soaked cotton tip applicators. On days 1, 3, 5, 7, and 10 postinfection, vaginal swabs were collected, added to 2.0 ml of medium, and frozen until titrated for infectious virus. On days 2, 5, and 8 postinoculation, three animals from each virus group were killed, sacral-dorsal root ganglia were removed, homogenized in 1.0 ml of medium, clarified at 600 g, and serial tenfold dilutions were assayed on RK cells for infectious virus. Determination oflatent virus infections. The frequency of establishment of latency and the quantity of latent virus recovered per ganglion were determined in groups of five animals per virus, following either ocular, intranasal, or genital inoculation. In representative experiments, bilateral trigeminal and sacral-dorsal ganglia were removed from surviving animals. The procedures for virus reactivation and for measurement of latent virus have been previously described (22) . Briefly, ganglia were incubated in culture tubes with 1 ml of growth medium for 5-7 d in a CO2 incubator to reactivate latent virus. Ganglia were then homogenized and titered in BSC-1 or RK cells. Representative ganglia were stored at -95°C for DNA extraction.
Isolation ofDNA from ganglia and analysis on ganglionic DNA for viral DNA sequences by polymerase chain reaction. Isolation and extraction of DNA from mouse ganglia have been described (24) . The primers, probes, and the reaction conditions used in the PCR reaction and the Southern blot analysis of the PCR products were identical to those as described (24) , except that washing procedures of the Southern blots were carried out at 460C rather than 50'C as reported.
Results
Replication ofmutants in vitro Replication competence of HSV-I (F), R3616, R4009, and HSV-1 (F)R was determined in MEF cells. The moi was 0.01. For HSV-1(F) and HSV-l(F)R, peak viral titers of 106 TCID50/ml ofsample were achieved 48-72 h after inoculation.
With R3616 and R4009, peak titers were attained later at 72-96 h after infection and at slightly lower quantities of 104 TCID50/ml of sample. Pathogenesis ofacute infection Intranasal infection. After intranasal inoculation of either HSV-1 (F) or HSV-1 (F) R in Swiss Webster mice, virus was readily detected in both the trigeminal ganglia and brain within three days of infection, as shown in Table I . The quantity of virus peaked -5 d after infection with both viruses. In contrast, R3616 and R4009 were not detected either in the ganglia or brain with the exception of one animal. Furthermore, the quantity ofvirus detected in the brain ofthis mouse was significantly lower than that following infection with HSV-l (F) or HSV-l (F)R. We repeated these experiments in Balb/C mice and obtained virtually identical results.
Ocular infection. As shown in Table II , HSV-1(F) and HSV-l (F)R also replicated well in corneal tissue of Balb/C mice. All animals became infected and the quantity of virus recovered was similar for both viruses. In contrast, R3616 and at 3,6,9, 12, and 24 h after inoculation. Virus was cleared from all animals by 9 h after infection. As shown in Table III, 3 d after intravaginal inoculation of Balb/c mice, peak quantities of HSV-1(F) and HSV-1(F)R could be detected in vaginal secretions. All animals became infected and remained so throughout the 7-d study. In contrast, R4009 and R3616 viruses were readily detected during the first 3 days; however, peak titers were lower and these viruses were cleared faster. Furthermore, R4009 was detectable in the genital tract of the Balb/C mice on day 7, whereas R3616 was not.
Manifestations of disease was greatest with HSV-1 (F) and HSV-1(F)R, consisting of edema, intense erythema, and numerous ulcerative lesions. In contrast, clinical disease was less evident in mice infected with R4009 or R3616. Among mice infected with these viruses, erythema was present in all animals but only on days 1 and 3. Whereas no Balb/C mouse developed hind limb paralysis or death following vaginal inoculation with R4009 and R3616, 20% of animals infected with HSV-l (F) and HSV-1 (F)R developed hind limb paralysis.
These studies were repeated and extended in Swiss Webster mice. The results oftwo separate experiments investigating the differences in the ability ofthese four viruses to replicate in the genital tract and spinal ganglia, cause diseases, and become reactivated on explantation of sacral ganglia, are illustrated in Table IV and Fig. 2 A. Several conclusions are relevant: (a) The peak vaginal virus titer of HSV-l (F) and HSV-l (F)R from day 1 to day 8 was, on the average, over 100-fold greater than that of R3616 or R4009. (b) In these experiments, we detected larger quantities ofboth R3616 and R4009 than those performed in the Balb/c mice but still significantly less than that found in the mice infected with HSV-1(F) or HSV-1 (F)R. Virus replication of the mutants in the vaginal tract was of shorter duration compared to the parental and restored viruses. (c) There was no mortality in mice infected with either R3616 or R4009 whereas the mortality exceeded 50% for both HSV-l (F) and HSV-1 (F)R (Table IV) swabs at 3, 6, 9, 12, and 24 h after infection. All animals cleared the input inoculum by 12 h. As shown in Fig. 2 B and Table V , the peak virus titers in vaginal swabs from guinea pigs infected with R3616 and R4009 was lower by a factor of 10-to 100-fold compared to HSV-l (F) and HSV-I (F)R. Larger quantities of both HSV-I (F) and HSV-I (F) R for longer periods of time were detected compared to R3616 and R4009.
Guinea pigs inoculated with HSV-l (F) developed external lesions on the genital skin with peak scores of 1.5. In contrast, animals inoculated with HSV-l (F)R, R3616, and R4009 rarely developed a genital lesion.
We were unable to detect infectious or latent virus in the ganglia ofguinea pigs infected with R3616 or R4009. However, only 2 of 18 animals which received wild-type or restored virus had virus detectable in the ganglia during either acute or latent infection.
Reactivation oflatent virus from murine ganglia. One objective of these studies was to determine whether the mutants incapable ofexpressing y134.5 established latency and could be reactivated. Bilateral trigeminal and sacral-dorsal ganglia ofinfected mice were tested for the presence of reactivable virus. HSV-l (F) and HSV-l (F)R were recovered uniformly from both trigeminal (Table I and Table II ) and sacral ganglia (Tables III and IV). The quantities of virus present in these infected ganglia were 107 pfu from trigeminal ganglia of Swiss Webster mice inoculated intranasally and 7.0 X 105 and 7.0 x 104 pfu from the trigeminal ganglia of Balb/C mice inoculated by the ocular route. Approximately 107 pfu (both viruses) from the sacral ganglia ofSwiss Webster mice inoculated intravaginally were recovered (Table IV) . In contrast, R3616 could be detected in only one ofthe 30 trigeminal ganglia tested in these studies and R4009 was found in only three trigeminal ganglia.
Analyses of murine trigeminal ganglia for the presence of latent virus by polymerase chain reaction. Trigeminal ganglia from mice infected with HSV-1(F), R4009, R3616, and mock infected mice were tested 30 d after infection with these viruses. As shown in Fig. 3 , viral DNA was readily detected in mice infected with HSV-I (F). The average quantity of virus recovered was -0.1 viral DNA equivalent/ganglionic cell DNA equivalent. In contrast, the amounts ofR36 16 and R4009 were much lower; in the few ganglia that were positive, only between 0.001 and 0.01 viral DNA equivalents per ganglionic cell DNA equivalent were obtained.
Discussion
The studies described in this report extend the previous observations that HSV-l mutants lacking a functional y 134.5 gene were incapable of replicating in and destroying the CNS of (26, 27) . These deletion mutants could only be reactivated at a very low frequency. One explanation for this observation is that the in the absence of replication in the cornea and nasopharynx, the amount ofvirus which reached the trigeminal neurons and CNS were considerably lower than that which reached the sacral ganglia from the vaginal tract-a site at which the virus did multiply. We should also note recovery of reactivated virus depends on its ability to multiply initially in the sensory neuron and subsequently in the cocultivated nonneuronal cells. Inasmuch as R3616 does not multiply efficiently in neuronal cells in situ, it is conceivable that the small amount of virus recovered from sensory ganglia may represent neuronal cells with a very high genome copy number.
(c) Our studies suggest that the y 34.5 mutants exhibit properties desirable in an ideal attenuated HSV-1 vaccine. This conclusion is based on the recognition that, above all other manifestations ofpathology induced by HSV, the most hazardous to health is the ability ofthis virus to access and replicate in the CNS ofboth newborn and adults. In consequence, elimination ofthe capacity ofHSV to multiply in the CNS and, coincidentally in the eye (a major cause of blindness in developed societies), would be a major safety requirement of for a live HSV vaccine. We should note, however, that it is possible to over-attenuate a HSV mutant and, therefore, negate its utility as a vaccine ( 11) .
(d) The observation that the 'y,34.5 virus fails to replicate in the CNS could potentially be exploited to selectively destroy tumor cells without affecting CNS tissue, as has recently been reported (28, 29) . Specifically, when R3616 is inoculated directly into glioma cell lines in vitro, viral replication progresses without impediment. Recently, we reported that the 34.5 gene functions to prevent virus mediated shut-off of protein synthesis in neuroblastoma cells (30) . These observations may have relevance for adjunctive therapy of CNS tumors of nonneuronal origin.
Among the many remaining unresolved questions are the actual functions of y134.5 at the molecular level, its precise role in the pathogenesis of disease(s), and whether the immune response to the gene product is a determinant ofthe outcome of infection. Studies designed to resolve these issues are in progress.
